Focus: Acrivon Therapeutics is a checkpoint inhibitor-focused oncology biotech based in Watertown, MA, currently in early clinical stages with a lean pipeline.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Best suited for early-career clinical or biostatistics professionals seeking oncology expertise and meaningful project ownership, but carry significant financial and milestone risk compared to better-capitalized peers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Acrivon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Acrivon Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ACRV Stock Price, Quote & Chart - ChartMill
ACRV Stock Price, Quote & Chart ChartMill
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move Stock Titan
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit GlobeNewswire
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit Quiver Quantitative
Acrivon CEO to join TD Cowen cancer innovation webcast May 26 - Stock Titan
Acrivon CEO to join TD Cowen cancer innovation webcast May 26 Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles